window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

Revolutionizing drug development: Novigenix unveils AI-powered RNA analysis for immune response profiling

By |2024-06-17T20:37:37+02:0017 January 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as

Novigenix appoints Dr. Pedro Romero as Chief Medical & Scientific Officer

By |2024-05-02T16:11:45+02:005 January 2024|News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions,  recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix. In

Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM

By |2024-04-22T21:46:41+02:004 October 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for

Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas

By |2024-04-22T21:53:09+02:0030 June 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND –  Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society

Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs

By |2024-04-22T21:53:25+02:0015 May 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune

Novigenix announces first closing of its $20M Series B financing round

By |2024-04-22T21:56:04+02:0016 November 2022|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s

Novigenix announces discovery of liquid biopsy immunotherapy response biomarkers in metastatic Melanoma

By |2024-04-22T21:57:18+02:009 September 2022|Communiqué de presse, News Novigenix|

New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients LAUSANNE, SWITZERLAND - September 9th, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of

Novigenix and Philips Sign Technology License Agreement for Prostate Cancer Precision Oncology Products

By |2024-06-17T20:20:03+02:009 March 2022|Communiqué de presse, News Novigenix|

New precision solutions may be accessible on Philips IntelliSpace Precision Medicine Platform   LAUSANNE, SWITZERLAND - March 8, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to

Novigenix and Radboud University Medical Center Discover the First Blood-Based ImmunoTranscriptomic biomarkers for Response to Anti-PD-1 therapy

By |2024-06-17T20:21:30+02:0028 September 2021|Communiqué de presse, News Novigenix|

Publication in Cancers Journal Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 LAUSANNE, SWITZERLAND - September 23rd, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced release of the article: “Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell

Novigenix Announces Election of Dr. Miro Venturi to its Board of Directors

By |2024-06-17T20:34:20+02:0031 August 2021|Communiqué de presse, News Novigenix|

 Company expands precision medicine solutions for drug development and clinical utility programs. LAUSANNE, SWITZERLAND - August 31, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced election of Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently Group CEO of Sintetica SA,

Go to Top